Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07137910) titled 'A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)' on Aug. 15.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Ausper Biopharma Co., Ltd.
Condition:
Chronic Hepatitis B
Intervention:
Drug: AHB-137
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: August 27, 2025
Target Sample Size: 60
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07137910...